©2015, CMDBioscience, Inc. 5 Science Park, New Haven, CT 06511 All Rights Reserved.
CMDBioscience is pursuing wholly owned, partnered and platform peptide drug discovery programs with leading pharmaceutical and biotech companies and academic groups. We welcome inquires from interested parties about our current programs and suggestions for future programs.
CMDBioscience is leveraging CMDInventus and cutting edge and validated biology to develop a franchise around peptide induced endogenous stem/progenitor cell mobilization and immunotherapy - two huge market opportunities. And while both approaches have broad clinical applications, our current focus is to exploit their therapeutic potentials in the acute myeloid leukemia (AML) and B cell follicular lymphoma settings.
Our wholly owned AML program is being pursued in collaboration with key opinion leaders (KOLs) at Washington University and is focused on developing novel peptide poly-pharmacology to mobilize and chemosensitize acute myeloid leukemia (AML) cells. Such an approach can be synergized with existing and future therapies to produce superior clinical outcomes for leukemia patients.
Our wholly owned lymphoma program is being pursued in partnership with another KOL at Mayo Clinic and is focused on developing peptides to activate T-cell mediated anti-lymphoma immuno-therapy.
If you are interested in learning more about the BD opportunities surrounding our wholly owned programs, please contact us. Similarly, if you would like to propose a new program for our consideration, please contact us.
CMDBioscience is open to developing partnered drug discovery programs with risk and reward sharing. Currently, we are executing on one such program with a pharmaceutical and academic partner. The program is leveraging a proprietary protein-protein crystal as an input for the computer-enabled, scaffold-based design of novel peptide-based macrocyclic inhibitors. The program has potential clinical implications for a range of diseases, including infectious, oncological and inflammatory disease. The program involves mutual expertise sharing, cost sharing and reward and IP sharing.
If you are interested in learning more about the BD opportunities surrounding our current partnered program or would like to propose a new BD opportunity, please contact us.
CMDBioscience is executing on revenue generating drug discovery collaborations with external partners and seeks additional platform program partnering opportunities with leading pharmaceutical companies. Platform programs provide our partners with access to our computational peptide drug design platform, CMDInventus. Platform programs typically involve partners supplying us with potential targets which we use as inputs to CMDInventus to generate peptide hits or leads. More modest platform partnering opportunities exist as well. For example, CMDInventus can be used to study previously identified peptide hits or leads and suggest fruitful avenues for future research. We are also interested in hearing from scientists who would like to contribute to the ongoing development of CMDInventus.
If you are interested in learning more about platform partnering opportunities, please contact us.